Loading...
Docoh

Checkmate Pharmaceuticals (CMPI)

Checkmate Pharmaceuticals, Inc. operates as a biotechnology company. The Company discovers and develops novel approaches for cancer immunotherapy such as immuno-oncology. Checkmate Pharmaceuticals serves patients worldwide.

Company profile

CMPI stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

12 May 22
30 Sep 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 39.5M 39.5M 39.5M 39.5M 39.5M 39.5M
Cash burn (monthly) 3.73M (no burn) 5.3M 5.26M 3.56M 4.17M
Cash used (since last report) 22.4M n/a 31.78M 31.59M 21.34M 25.04M
Cash remaining 17.1M n/a 7.72M 7.9M 18.15M 14.45M
Runway (months of cash) 4.6 n/a 1.5 1.5 5.1 3.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
31 May 22 Alan Bash Stock Option Common Stock Sale back to company Dispose D No No 2.99 575,000 1.72M 0
31 May 22 Fuhrman Alan Stock Option Common Stock Sale back to company Dispose D No No 2.62 22,736 59.57K 0
31 May 22 Fuhrman Alan Stock Option Common Stock Sale back to company Dispose D No No 6.27 10,030 62.89K 0
31 May 22 Fuhrman Alan Stock Option Common Stock Sale back to company Dispose D No No 3.93 246,671 969.42K 0
31 May 22 Jon Marc Wigginton Stock Option Common Stock Sale back to company Dispose D No No 2.19 20,061 43.93K 0
31 May 22 James Wooldridge Stock Option Common Stock Sale back to company Dispose D No No 2.62 95,916 251.3K 0
31 May 22 James Wooldridge Stock Option Common Stock Sale back to company Dispose D No No 15 150,818 2.26M 0
31 May 22 James Wooldridge Stock Option Common Stock Sale back to company Dispose D No No 5.09 27,300 138.96K 0
31 May 22 James Wooldridge Stock Option Common Stock Sale back to company Dispose D No No 2.05 101,180 207.42K 0
31 May 22 James Wooldridge Stock Option Common Stock Sale back to company Dispose D No No 13.5 54,600 737.1K 0
61.2% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 24 9 +166.7%
Opened positions 16 0 NEW
Closed positions 1 22 -95.5%
Increased positions 1 1
Reduced positions 4 2 +100.0%
13F shares Current Prev Q Change
Total value 43.06M 6.41M +571.7%
Total shares 13.5M 4.4M +206.5%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Sofinnova Investments 3.61M $11.51M NEW
Novo Holdings A/S 2.16M $6.9M -0.4%
Medicxi Ventures Management 1.5M $4.79M 0.0%
Omega Fund Management 1.34M $4.26M NEW
Decheng Capital Management III 1.33M $4.25M NEW
Clough Capital Partners L P 1.14M $3.63M NEW
FMR 966.23K $3.08M NEW
Vanguard 556.42K $1.78M NEW
Sectoral Asset Management 541.77K $1.73M -0.0%
Bridgeway Capital Management 106.5K $340K NEW
Largest transactions Shares Bought/sold Change
Sofinnova Investments 3.61M +3.61M NEW
Omega Fund Management 1.34M +1.34M NEW
Decheng Capital Management III 1.33M +1.33M NEW
Clough Capital Partners L P 1.14M +1.14M NEW
FMR 966.23K +966.23K NEW
Vanguard 556.42K +556.42K NEW
Bridgeway Capital Management 106.5K +106.5K NEW
Ensign Peak Advisors 0 -93.33K EXIT
RBF Capital 68.03K +68.03K NEW
FHI Federated Hermes 30.64K +30.64K NEW

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: anesthesiologist, ASP, Attorney, Australia, baby, Bash, booster, Brazil, BrightEdge, Cadillac, CDPA, certified, Chairman, circumstance, Clough, Colorado, Connecticut, consecutive, consolidatedfinancial, CPA, CPRA, CSCC, customary, Decheng, Delta, device, doubt, driven, excise, exploring, flexibility, flow, formation, gave, geopolitical, GLP, governor, identification, inquiry, instated, intertumoral, labor, legislature, Longitude, mark, MCC, Medixci, merge, Mexico, moratorium, Novo, Omega, Omicron, Online, organizational, overhead, Parent, pendency, prominent, repurchase, resignation, Russia, Russian, Scandinavian, Sectoral, seller, Singapore, Society, Sofinnova, standalone, stringent, theongoing, therewith, tied, timeframe, timetable, today, trialin, UCPA, Ukraine, unfounded, unused, Utah, vast, venBio, venture, Virginia, withholding, witnessed, York
Removed: affiliate, affiliated, Alliance, announcing, attributable, augment, carried, closed, commensurate, comprised, concluding, conversion, cumulative, deducting, depreciation, designing, director, discontinued, discussed, dosed, effected, employ, exercised, exhaust, expanded, formally, function, inclusive, intention, investigation, KGaA, Kuro, lacked, monotherapy, mutual, outlined, overallotment, paper, par, permission, precautionary, preferential, rating, reclassified, redesigned, reliable, remediate, remediated, reportable, resultant, safest, segregation, split, unaffected, undergoing, underwriting, undesignated, unpaid, website

Patents

Utility
Packaging Oligonucleotides into Virus-like Particles
26 Aug 21
The present invention relates to processes for producing compositions comprising (i) a virus-like particle of an RNA bacteriophage, and (ii) aggregated oligonucleotides, wherein said aggregated oligonucleotides are packaged into said virus-like particle.
Utility
Synthetic Rig-i-like Receptor Agonists
8 Jul 21
The present disclosure relates to, inter alia, RNA molecules (e.g., RNA hairpin agonists) that bind to and agonize RIG-I-like receptors (RLRs), and to use of the molecules in methods for treating, or ameliorating one or more symptoms of, a disorder (e.g., cancer).
Utility
Compositions and Methods for Tumor Immunotherapy
4 Feb 21
Provided are compositions and methods for treating cancer using administration of certain volumes of CpG oligonucleotides (CpG ODN) and, optionally, administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody.
Utility
Synthetic RIG-I-like receptor agonists
2 Feb 21
The present disclosure relates to, inter alia, RNA molecules (e.g., RNA hairpin agonists) that bind to and agonize RIG-I-like receptors (RLRs), and to use of the molecules in methods for treating, or ameliorating one or more symptoms of, a disorder (e.g., cancer).
Utility
Combination Tumor Immunotherapy
9 Sep 20
Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CLA-4 antibody.